Posted on September 29, 2015 by Sitemaster
According to a presentation given at the European Cancer Congress, currently ongoing in Vienna, Austria, a small, recently completed Phase III trial has shown that orteronel (TAK-700) might have had some value in treatment of late stage prostate cancer after all. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, maintenance, mCRPC, metastatic, orteronel, post-chemotherapy, TAK-700 | 3 Comments »
Posted on June 19, 2014 by Sitemaster
As previously reported, Takeda’s orteronel (also known as TAK-700), which had been in Phase III clinical trials in metastatic, castration-resistant prostate cancer (mCRPC), failed to demonstrate a survival benefit in either of the two pivotal trials. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: orteronel, TAK-700 | 1 Comment »
Posted on June 1, 2014 by Sitemaster
We commented earlier on several of the prostate cancer presentations given this morning at the American Society for Clinical Oncology (ASCO) meeting — see here and here. However, there was another important paper presented this morning. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant, mCRPC, metastatic, orteronel, TAK-700 | Leave a comment »
Posted on July 26, 2013 by Sitemaster
Takeda Pharmaceutical Co. has unblinded the Phase III clinical trial of ortoronel + prednisone in treatment of men with progressive, metastatic, castration-resistant prostate cancer (mCRPC) who had been previously treated with at least one cycle of docetaxel-based chemotherapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, mCRPC, metastatic, ortoronel, post-chemotherapy, TAK-700 | 1 Comment »
Posted on May 2, 2013 by Sitemaster
It has been brought to our attention that the Southwest Oncology Group (SWOG) has initiated a new, randomized, double-blind, multi-center, Phase III trial designed to compare androgen deprivation therapy (ADT) + bicalutamide (Casodex) to ADT + the investigational drug TAK-700 in men newly diagnosed with metastatic, hormone-sensitive prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, hormone-sensitive, metastatic, orteronel, TAK-700 | 9 Comments »
Posted on January 2, 2013 by Sitemaster
Although the company has made no formal announcement, we have been advised that Takeda has, in fact, completed enrollment of patients into the two pivotal Phase III clinical trials of orteronel (TAK-700) for the treatment of patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: enrollment, orteronel, TAK-700, trial | Leave a comment »
Posted on February 9, 2012 by Sitemaster
Has the clinical success of some new drugs started to affect enrollment in trials of others for advanced forms of prostate cancer? … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ipilimumab, TAK-700, tasquinimod, trials | Leave a comment »
Posted on June 2, 2011 by Sitemaster
A story on the Bloomberg.com web site gives information about a patient with castration-resistant prostate cancer (CRPC) who has had a zero-level PSA for 40 months since starting on a clinical trial of abiraterone actetate in early 2008. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, CRPC, orteronel, survival, TAK-700 | 3 Comments »
Posted on November 4, 2010 by Sitemaster
According to a media release earlier today, Millennium and its parent company Takeda Pharmaceutical have initiated a randomized, double-blind, multi-center, Phase III clinical trial of TAK-700 (to be known in the future as Ortoronel) for the treatment of patients with chemotherapy-naïve, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development | Tagged: castration-resistant, mCRPC, metastatic, TAK-700, trial | 8 Comments »
Posted on September 11, 2009 by Sitemaster
According to a media release issued earlier today, Takeda Pharmaceuticals and it’s wholly owned subsidiary, Millennium, are starting the Phase II portion of a Phase I/II clinical trial of TAK-700 in patients with advanced prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: castration-resistant prostate cancer, CRPC, TAK-700 | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 